Fat-Loss Protocol

Goal

Drive fat loss (especially visceral) while preserving lean mass — by combining appetite/insulin control, GH-driven lipolysis, mitochondrial fat-oxidation, and a behavior base.

Provenance & framing

Research/educational only; not medical advice. Peptide claims are [anecdote]/[protocol] from the cited transcripts — see each peptide note for sources. Build only with a physician.

Why it synergises (three layers)

• Peptides: a GLP-1 (Tirzepatide/Retatrutide) controls appetite + insulin sensitivity; a GH secretagogue (Tesamorelin + Ipamorelin) drives visceral-fat loss and helps spare muscle; MOTS-C boosts fat oxidation / mitochondrial capacity.
• Behaviors: Fasted Cardio/Zone 2 Cardio/Endurance Training for fat oxidation, HIIT for an exercise GH pulse, and Resistance Training + adequate protein to preserve lean mass (the key to not losing muscle on a GLP-1). Fasting amplifies the same lipolysis/AMPK/GH levers.
• This is the body-recomposition half of the “trinity” (minus androgen modulation).

Timing & intake

• GLP-1: micro-dose, titrate slowly, keep loss ≤2 lb/week (preserve lean mass). GH secretagogue pre-sleep (no carbs ~45 min–2 h prior) and/or a morning dose 30 min before Fasted Cardio; MOTS-C 30 min pre-aerobic-exercise. Resistance training on its own schedule.

Cautions & interactions

• [warning] GH secretagogues can reduce insulin sensitivity (worse without visceral-fat loss); GLP-1s cause muscle loss without resistance training + protein; cold plunge not within 4–8 h post-resistance-training if hypertrophy matters. Titrate everything.

Evidence backing

• Visceral-fat / GH: Tesamorelin, Ipamorelin (see their cited papers); mitochondrial fat oxidation: MOTS-C; GLP-1 weight loss: Tirzepatide/Retatrutide. Applied dosing: Koniver (‘fat-loss peptide’ stack), GH selection, MOTS-C.

Monitoring

• Fasting glucose/insulin/A1C (insulin-resistance risk), lean mass, weight-loss rate (≤2 lb/wk).